Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04091087 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT04091087 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 66 participants.
The verdict
NCT04091087, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
This is a Phase 2a, randomized, double blind, vehicle controlled, parallel group, proof of concept study that will include participants with stasis dermatitis without active skin ulceration, who will receive crisaborole ointment 2% or vehicle twice daily for 6 weeks.
Interventions
- DRUG crisaborole ointment
- OTHER vehicle ointment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2020-06-26 |
| Est. Completion | 2021-10-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04091087
The ClinicalTrials.gov registry entry for NCT04091087 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which crisaborole ointment is the first listed.
NCT04091087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04091087 about?
NCT04091087 is a clinical study titled "Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis". This is a Phase 2a, randomized, double blind, vehicle controlled, parallel group, proof of concept study that will include participants with stasis dermatitis without active skin ulceration, who will receive crisaborole ointment 2% or vehicle twice daily for 6 weeks.
What is the current status of trial NCT04091087?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2020-06-26. Estimated completion is 2021-10-19.
What interventions are being tested in trial NCT04091087?
The interventions under investigation include: crisaborole ointment (DRUG), vehicle ointment (OTHER).
Who is sponsoring clinical trial NCT04091087?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.